{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:09:13Z","timestamp":1791338953640,"version":"4.3.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a possible role for oxidative stress, a state characterized by an altered balance between the production of free radicals or reactive oxygen species (ROS) and antioxidant defences, in coronavirus disease 2019 (COVID-19), the genesis of which is quite complex. Excessive oxidative stress could be responsible for the alveolar damage, thrombosis, and red blood cell dysregulation observed in COVID-19. Apparently, deficiency of glutathione (GSH), a low-molecular-weight thiol that is the most important non-enzymatic antioxidant molecule and has the potential to keep the cytokine storm in check, is a plausible explanation for the severe manifestations and death in COVID-19 patients. Thiol drugs, which are considered mucolytic, also possess potent antioxidant and anti-inflammatory properties. They exhibit antibacterial activity against a variety of medically important bacteria and may be an effective strategy against influenza virus infection. The importance of oxidative stress during COVID-19 and the various pharmacological characteristics of thiol-based drugs suggest a possible role of thiols in the treatment of COVID-19. Oral and intravenous GSH, as well as GSH precursors such as N-acetylcysteine (NAC), or drugs containing the thiol moiety (erdosteine) may represent a novel therapeutic approach to block NF-kB and address the cytokine storm syndrome and respiratory distress observed in COVID-19 pneumonia patients<\/jats:p>","DOI":"10.1007\/s00408-021-00465-3","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T01:02:36Z","timestamp":1630026156000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Use of Thiols in the Treatment of COVID-19: Current Evidence"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep Santosh","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josuel","family":"Ora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"issue":"2 Suppl 1","key":"465_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0026-0495(00)80077-3","volume":"49","author":"DJ Betteridge","year":"2000","unstructured":"Betteridge DJ (2000) What is oxidative stress? Metabolism 49(2 Suppl 1):3\u20138","journal-title":"Metabolism"},{"issue":"6809","key":"465_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/35041687","volume":"408","author":"T Finkel","year":"2000","unstructured":"Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239\u2013247","journal-title":"Nature"},{"issue":"2","key":"465_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bcp.2010.10.001","volume":"81","author":"NS Gould","year":"2011","unstructured":"Gould NS, Day BJ (2011) Targeting maladaptive glutathione responses in lung disease. Biochem Pharmacol 81(2):187\u2013193","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"465_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1134\/S0006297920120068","volume":"85","author":"BV Chernyak","year":"2020","unstructured":"Chernyak BV, Popova EN, Prikhodko AS, Grebenchikov OA, Zinovkina LA, Zinovkin RA (2020) COVID-19 and oxidative stress. Biochemistry (Mosc) 85(12):1543\u20131553","journal-title":"Biochemistry (Mosc)"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"100897","DOI":"10.1016\/j.nmni.2021.100897","volume":"42","author":"B Karkhanei","year":"2021","unstructured":"Karkhanei B, Ghane ET, Mehri F (2021) Evaluation of oxidative stress level: total antioxidant capacity, total oxidant status and glutathione activity in patients with Covid-19. New Microbes New Infect 42:100897","journal-title":"New Microbes New Infect"},{"issue":"2","key":"465_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/antiox10020257","volume":"10","author":"J Pincemail","year":"2021","unstructured":"Pincemail J, Cavalier E, Charlier C, Cheramy-Bien JP, Brevers E, Courtois A, Fadeur M, Meziane S, Goff CL, Misset B, Albert A, Defraigne JO, Rousseau AF (2021) Oxidative stress status in COVID-19 patients hospitalized in intensive care unit for severe pneumonia. A Pilot Study. Antioxidants (Basel) 10(2):257","journal-title":"Antioxidants (Basel)"},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"105996","DOI":"10.1016\/j.rmed.2020.105996","volume":"168","author":"F Perrotta","year":"2020","unstructured":"Perrotta F, Matera MG, Cazzola M, Bianco A (2020) Severe respiratory SARS-CoV2 infection: does ACE2 receptor matter? Respir Med 168:105996","journal-title":"Respir Med"},{"key":"465_CR8","doi-asserted-by":"publisher","first-page":"100741","DOI":"10.1016\/j.jbior.2020.100741","volume":"77","author":"G Sch\u00f6nrich","year":"2020","unstructured":"Sch\u00f6nrich G, Raftery MJ, Samstag Y (2020) Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul 77:100741","journal-title":"Adv Biol Regul"},{"issue":"6","key":"465_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"F Scialo","year":"2020","unstructured":"Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G, Bianco A (2020) ACE2: the major cell entry receptor for SARS-CoV-2. Lung 198(6):867\u2013877","journal-title":"Lung"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","volume":"11","author":"D Ragab","year":"2020","unstructured":"Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol 11:1446","journal-title":"Front Immunol"},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"118617","DOI":"10.1016\/j.lfs.2020.118617","volume":"264","author":"G Morris","year":"2021","unstructured":"Morris G, Bortolasci CC, Puri BK, Olive L, Marx W, O\u2019Neil A, Athan E, Carvalho A, Maes M, Walder K, Berk M (2021) Preventing the development of severe COVID-19 by modifying immunothrombosis. Life Sci 264:118617","journal-title":"Life Sci"},{"issue":"9","key":"465_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41577-020-0407-1","volume":"20","author":"M Laforge","year":"2020","unstructured":"Laforge M, Elbim C, Fr\u00e8re C, H\u00e9madi M, Massaad C, Nuss P, Benoliel JJ, Becker C (2020) Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol 20(9):515\u2013516","journal-title":"Nat Rev Immunol"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.niox.2020.06.002","volume":"102","author":"J Wu","year":"2020","unstructured":"Wu J (2020) Tackle the free radicals damage in COVID-19. Nitric Oxide 102:39\u201341","journal-title":"Nitric Oxide"},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"118653","DOI":"10.1016\/j.lfs.2020.118653","volume":"264","author":"BM Bakadia","year":"2021","unstructured":"Bakadia BM, Boni BOO, Ahmed AAQ, Yang G (2021) The impact of oxidative stress damage induced by the environmental stressors on COVID-19. Life Sci 264:118653","journal-title":"Life Sci"},{"issue":"7","key":"465_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/antiox9070624","volume":"9","author":"F Silvagno","year":"2020","unstructured":"Silvagno F, Vernone A, Pescarmona GP (2020) The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants (Basel) 9(7):624","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"465_CR16","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/acsinfecdis.0c00288","volume":"6","author":"A Polonikov","year":"2020","unstructured":"Polonikov A (2020) Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis 6(7):1558\u20131562","journal-title":"ACS Infect Dis"},{"issue":"4","key":"465_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/jcm9040941","volume":"9","author":"IJ Borges do Nascimento","year":"2020","unstructured":"Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT, Marusic A, Jeroncic A, Carvas Junior N, Pericic TP, Zakarija-Grkovic I, Meirelles Guimar\u00e3es SM, Luigi Bragazzi N, Bjorklund M, Sofi-Mahmudi A, Altujjar M, Tian M, Arcani DMC, O\u2019Math\u00fana DP, Marcolino MS (2020) Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 9(4):941","journal-title":"J Clin Med"},{"issue":"26","key":"465_CR18","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1021\/acsomega.0c02125","volume":"5","author":"S Hati","year":"2020","unstructured":"Hati S, Bhattacharyya S (2020) Impact of thiol-disulfide balance on the binding of Covid-19 spike protein with angiotensin-converting enzyme 2 receptor. ACS Omega 5(26):16292\u201316298","journal-title":"ACS Omega"},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"101902","DOI":"10.1016\/j.redox.2021.101902","volume":"41","author":"D Giustarini","year":"2021","unstructured":"Giustarini D, Santucci A, Bartolini D, Galli F, Rossi R (2021) The age-dependent decline of the extracellular thiol-disulfide balance and its role in SARS-CoV-2 infection. Redox Biol 41:101902","journal-title":"Redox Biol"},{"issue":"5","key":"465_CR20","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","volume":"1830","author":"SC Lu","year":"2013","unstructured":"Lu SC (2013) Glutathione synthesis. Biochim Biophys Acta 1830(5):3143\u20133153","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"465_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","volume":"141","author":"GF Rushworth","year":"2014","unstructured":"Rushworth GF, Megson IL (2014) Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 141(2):150\u2013159","journal-title":"Pharmacol Ther"},{"issue":"7","key":"465_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2019.04.015","volume":"40","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG (2019) Thiol-based drugs in pulmonary medicine: much more than mucolytics. Trends Pharmacol Sci 40(7):452\u2013463","journal-title":"Trends Pharmacol Sci"},{"issue":"17","key":"465_CR23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s40265-020-01412-x","volume":"80","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG (2020) Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs 80(17):1799\u20131809","journal-title":"Drugs"},{"issue":"8","key":"465_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/17476348.2018.1495562","volume":"12","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Matera MG, Rogliani P, Cazzola M (2018) Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med 12(8):693\u2013708","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"465_CR25","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s10753-016-0393-4","volume":"39","author":"JS Park","year":"2016","unstructured":"Park JS, Park MY, Cho YJ, Lee JH, Yoo CG, Lee CT, Lee SM (2016) Anti-inflammatory effect of erdosteine in lipopolysaccharide-stimulated RAW 2647 cells. Inflammation 39(4):1573\u20131581","journal-title":"Inflammation"},{"issue":"1","key":"465_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pupt.2005.12.007","volume":"20","author":"AM Sadowska","year":"2007","unstructured":"Sadowska AM, Manuel-Y-Keenoy B, De Backer WA (2007) Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 20(1):9\u201322","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"465_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12931-016-0500-y","volume":"18","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG (2017) Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res 18(1):26","journal-title":"Respir Res"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.04.011","volume":"103","author":"L Calzetta","year":"2018","unstructured":"Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG (2018) N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother 103:1\u20138","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"465_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0773.2003.920407.x","volume":"92","author":"YY Jang","year":"2003","unstructured":"Jang YY, Song JH, Shin YK, Han ES, Lee CS (2003) Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol 92(4):173\u2013179","journal-title":"Pharmacol Toxicol"},{"key":"465_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pupt.2018.10.005","volume":"53","author":"R Dal Negro","year":"2018","unstructured":"Dal Negro R, Pozzi E, Cella SG (2018) Erdosteine: drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulm Pharmacol Ther 53:80\u201385","journal-title":"Pulm Pharmacol Ther"},{"issue":"2\u20133","key":"465_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tox.2006.08.027","volume":"228","author":"R Demiralay","year":"2006","unstructured":"Demiralay R, G\u00fcrsan N, Erdem H (2006) Regulation of sepsis-induced apoptosis of pulmonary cells by posttreatment of erdosteine and N-aceylcysteine. Toxicology 228(2\u20133):151\u2013161","journal-title":"Toxicology"},{"issue":"17","key":"465_CR32","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.1128\/JB.00128-18","volume":"200","author":"ML Reniere","year":"2018","unstructured":"Reniere ML (2018) Reduce, induce, thrive: bacterial redox sensing during pathogenesis. J Bacteriol 200(17):e00128-e218","journal-title":"J Bacteriol"},{"issue":"3","key":"465_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00268-003-7402-0","volume":"28","author":"H Nygren","year":"2004","unstructured":"Nygren H, Malmberg P, Sahlin H (2004) Development of a wound dressing targeting neutrophil function. World J Surg 28(3):337\u2013342","journal-title":"World J Surg"},{"key":"465_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","volume":"117","author":"F Blasi","year":"2016","unstructured":"Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M (2016) The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med 117:190\u2013197","journal-title":"Respir Med"},{"issue":"4","key":"465_CR35","first-page":"344","volume":"49","author":"PC Braga","year":"1999","unstructured":"Braga PC, Dal Sasso M, Sala MT, Gianelle V (1999) Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung 49(4):344\u2013350","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"465_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.micinf.2017.08.008","volume":"19","author":"M Liu","year":"2017","unstructured":"Liu M, Chen F, Liu T, Chen F, Liu S, Yang J (2017) The role of oxidative stress in influenza virus infection. Microbes Infect 19(12):580\u2013586","journal-title":"Microbes Infect"},{"issue":"7","key":"465_CR37","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1183\/09031936.97.10071535","volume":"10","author":"S De Flora","year":"1997","unstructured":"De Flora S, Grassi C, Carati L (1997) Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 10(7):1535\u20131541","journal-title":"Eur Respir J"},{"issue":"5","key":"465_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2011.05.014","volume":"82","author":"M Mata","year":"2011","unstructured":"Mata M, Morcillo E, Gimeno C, Cortijo J (2011) N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 82(5):548\u2013555","journal-title":"Biochem Pharmacol"},{"key":"465_CR39","unstructured":"Van Hecke O, Lee J. N-acetylcysteine: a rapid review of the evidence for effectiveness in treating COVID-19. 2020. https:\/\/www.cebm.net\/covid-19\/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid-19\/."},{"issue":"2","key":"465_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/039463200702000215","volume":"20","author":"A Garozzo","year":"2007","unstructured":"Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A (2007) N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 20(2):349\u2013354","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"8","key":"465_CR41","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1681\/ASN.2004060458","volume":"16","author":"ME Ullian","year":"2005","unstructured":"Ullian ME, Gelasco AK, Fitzgibbon WR, Beck CN, Morinelli TA (2005) N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells. J Am Soc Nephrol 16(8):2346\u20132353","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"465_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/BF00558131","volume":"37","author":"LF Prescott","year":"1989","unstructured":"Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT (1989) The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 37(5):501\u2013506","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"465_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/bdd.2510110205","volume":"11","author":"L Borgstr\u00f6m","year":"1990","unstructured":"Borgstr\u00f6m L, K\u00e5gedal B (1990) Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos 11(2):131\u2013136","journal-title":"Biopharm Drug Dispos"},{"key":"465_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.redox.2017.09.005","volume":"14","author":"B Wang","year":"2018","unstructured":"Wang B, Yee Aw T, Stokes KY (2018) N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes. Redox Biol 14:218\u2013228","journal-title":"Redox Biol"},{"issue":"11","key":"465_CR45","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1007\/s00125-012-2685-z","volume":"55","author":"AT Treweeke","year":"2012","unstructured":"Treweeke AT, Winterburn TJ, Mackenzie I, Barrett F, Barr C, Rushworth GF, Dransfield I, MacRury SM, Megson IL (2012) N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia 55(11):2920\u20132928","journal-title":"Diabetologia"},{"key":"465_CR46","first-page":"801","volume":"30","author":"S Motor","year":"2014","unstructured":"Motor S, Alp H, Yuksel R, Sukru Erden E, Oktar S, Celik S, Cayirci G, Demirel YE (2014) The effects of erdosteine on coagulation in rats. Acta Medica Mediterranea 30:801\u2013804","journal-title":"Acta Medica Mediterranea"},{"issue":"10","key":"465_CR47","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0960327110396526","volume":"30","author":"V Arica","year":"2011","unstructured":"Arica V, Tutanc M, Ozturk OH, Arica S, Basarslan F, Erden ES, Oktar S, Kaya H (2011) Dual effects of erdosteine on hemostasis via its different metabolites in young rats. Hum Exp Toxicol 30(10):1644\u20131648","journal-title":"Hum Exp Toxicol"},{"key":"465_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejogrb.2014.10.018","volume":"183","author":"R Dokuyucu","year":"2014","unstructured":"Dokuyucu R, Karateke A, Gokce H, Kurt RK, Ozcan O, Ozturk S, Tas ZA, Karateke F, Duru M (2014) Antioxidant effect of erdosteine and lipoic acid in ovarian ischemia-reperfusion injury. Eur J Obstet Gynecol Reprod Biol 183:23\u201327","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"465_CR49","doi-asserted-by":"publisher","first-page":"110133","DOI":"10.1016\/j.mehy.2020.110133","volume":"144","author":"N Jaiswal","year":"2020","unstructured":"Jaiswal N, Bhatnagar M, Shah H (2020) N-acetycysteine: a potential therapeutic agent in COVID-19 infection. Med Hypotheses 144:110133","journal-title":"Med Hypotheses"},{"issue":"10","key":"465_CR50","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.1096\/fj.202001807","volume":"34","author":"S De Flora","year":"2020","unstructured":"De Flora S, Balansky R, La Maestra S (2020) Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J 34(10):13185\u201313193","journal-title":"FASEB J"},{"issue":"2","key":"465_CR51","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/antiox10020272","volume":"10","author":"AM Fratta Pasini","year":"2021","unstructured":"Fratta Pasini AM, Stranieri C, Cominacini L, Mozzini C (2021) Potential role of antioxidant and anti-inflammatory therapies to prevent severe SARS-Cov-2 complications. Antioxidants (Basel) 10(2):272","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"465_CR52","first-page":"2802","volume":"25","author":"RR Mohanty","year":"2021","unstructured":"Mohanty RR, Padhy BM, Das S, Meher BR (2021) Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. Eur Rev Med Pharmacol Sci 25(6):2802\u20132807","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"465_CR53","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2147\/JIR.S306849","volume":"14","author":"KK Wong","year":"2021","unstructured":"Wong KK, Lee SWH, Kua KP (2021) N-acetylcysteine as adjuvant therapy for COVID-19\u2014a perspective on the current state of the evidence. J Inflamm Res 14:2993\u20133013","journal-title":"J Inflamm Res"},{"key":"465_CR54","doi-asserted-by":"publisher","first-page":"106114","DOI":"10.1016\/j.rmed.2020.106114","volume":"171","author":"MG Matera","year":"2020","unstructured":"Matera MG, Rogliani P, Calzetta L, Cazzola M (2020) Pharmacological management of COVID-19 patients with ARDS (CARDS): a narrative review. Respir Med 171:106114","journal-title":"Respir Med"},{"issue":"1","key":"465_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"D Schoeman","year":"2019","unstructured":"Schoeman D, Fielding BC (2019) Coronavirus envelope protein: current knowledge. Virol J 16(1):69","journal-title":"Virol J"},{"key":"465_CR56","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/fmb-2020-0074","volume":"15","author":"JA Rangel-M\u00e9ndez","year":"2020","unstructured":"Rangel-M\u00e9ndez JA, Moo-Puc RE (2020) N-acetylcysteine as a potential treatment for COVID-19. Future Microbiol 15:959\u2013962","journal-title":"Future Microbiol"},{"key":"465_CR57","doi-asserted-by":"publisher","unstructured":"Grishin AM, Dolgova NV, Harms S, Pickering IJ, George GN, Falzarano D, Cygler M (2021) Spike protein disulfide disruption as a potential treatment for SARS-CoV-2. bioRxiv [Preprint]. https:\/\/doi.org\/10.1101\/2021.01.02.425099","DOI":"10.1101\/2021.01.02.425099"},{"key":"465_CR58","doi-asserted-by":"publisher","unstructured":"Guthappa R (2020) Molecular docking studies of N-acetyl cysteine, zinc acetyl cysteine and niclosamide on SARS Cov 2 protease and its comparison with hydroxychloroquine. Chemarxiv [Preprint]. https:\/\/doi.org\/10.26434\/chemrxiv.12161493.v1.","DOI":"10.26434\/chemrxiv.12161493.v1"},{"key":"465_CR59","doi-asserted-by":"publisher","unstructured":"Debnath U, Dewaker V, Prabhakar YS, Bhattacharyya P, Mandal A (2020) Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl cysteine, a molecular scissor: a probable strategy to combat COVID-19. ChemRxiv [Preprint]. https:\/\/doi.org\/10.26434\/chemrxiv.12687923.v1.","DOI":"10.26434\/chemrxiv.12687923.v1"},{"issue":"6","key":"465_CR60","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/15412555.2014.898040","volume":"11","author":"P Santus","year":"2014","unstructured":"Santus P, Corsico A, Solidoro P, Braido F, Di Marco F, Scichilone N (2014) Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD 11(6):705\u2013717","journal-title":"COPD"},{"issue":"21","key":"465_CR61","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1111\/bph.15230","volume":"177","author":"V Citi","year":"2020","unstructured":"Citi V, Martelli A, Brancaleone V, Brogi S, Gojon G, Montanaro R, Morales G, Testai L, Calderone V (2020) Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H2 S donors in COVID-19 therapy. Br J Pharmacol 177(21):4931\u20134941","journal-title":"Br J Pharmacol"},{"key":"465_CR62","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2020.8247","author":"AR Bourgonje","year":"2021","unstructured":"Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ (2021) N-Acetylcysteine and hydrogen sulfide in coronavirus disease 2019. Antioxid Redox Signal. https:\/\/doi.org\/10.1089\/ars.2020.8247 (Epub ahead of print)","journal-title":"Antioxid Redox Signal"},{"key":"465_CR63","doi-asserted-by":"publisher","first-page":"102041","DOI":"10.1016\/j.redox.2021.102041","volume":"45","author":"D Bartolini","year":"2021","unstructured":"Bartolini D, Stabile AM, Bastianelli S, Giustarini D, Pierucci S, Busti C, Vacca C, Gidari A, Francisci D, Castronari R, Mencacci A, DiCristina M, Focaia R, Sabbatini S, Rende M, Gioiello A, Cruciani G, Rossi R, Galli F (2021) SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. Redox Biol 45:102041","journal-title":"Redox Biol"},{"issue":"10","key":"465_CR64","first-page":"69","volume":"9","author":"R Bhattacharya","year":"2020","unstructured":"Bhattacharya R, Ghosh R, Kulshrestha M, Chowdhury S, Mukherjee R, Ray I (2020) Observational study on clinical features, treatment and outcome of COVID 19 in a tertiary care centre in India\u2014a retrospective case series. Intern J Sci Res 9(10):69\u201371","journal-title":"Intern J Sci Res"},{"key":"465_CR65","first-page":"491","volume":"9","author":"C Puyo","year":"2020","unstructured":"Puyo C, Kreig D, Saddi V, Ansari E, Prince O (2020) Case report: use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 positive patient. F1000Research 9:491","journal-title":"F1000Research"},{"issue":"42","key":"465_CR66","doi-asserted-by":"publisher","first-page":"e22577","DOI":"10.1097\/MD.0000000000022577","volume":"99","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wang M, Luo G, Qian X, Wu C, Zhang Y, Chen B, Leung EL, Tang Y (2020) Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: a case report. Medicine (Baltimore) 99(42):e22577","journal-title":"Medicine (Baltimore)"},{"key":"465_CR67","doi-asserted-by":"publisher","first-page":"108544","DOI":"10.1016\/j.clim.2020.108544","volume":"219","author":"H Ibrahim","year":"2020","unstructured":"Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, Yarta K, Staniloae C, Williams M (2020) Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol 219:108544","journal-title":"Clin Immunol"},{"key":"465_CR68","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.csbj.2021.02.009","volume":"19","author":"AP Chavarr\u00eda","year":"2021","unstructured":"Chavarr\u00eda AP, V\u00e1zquez RRV, Cherit JGD, Bello HH, Suastegui HC, Moreno-Casta\u00f1eda L, Alan\u00eds Estrada G, Hern\u00e1ndez F, Gonz\u00e1lez-Marcos O, Saucedo-Orozco H, Manzano-Pech L, M\u00e1rquez-Velasco R, Guarner-Lans V, P\u00e9rez-Torres I, Soto ME (2021) Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput Struct Biotechnol J 19:1379\u20131390","journal-title":"Comput Struct Biotechnol J"},{"key":"465_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1945675","author":"SF Assimakopoulos","year":"2021","unstructured":"Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, Oikonomou I, Mouzaki A, Marangos M (2021) N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort. Infect Dis (Lond). https:\/\/doi.org\/10.1080\/23744235.2021.1945675 (Epub ahead of print)","journal-title":"Infect Dis (Lond)"},{"key":"465_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.07.003","author":"SN Avdeev","year":"2021","unstructured":"Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikkhanov ZG (2021) N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2021.07.003 (Epub ahead of print)","journal-title":"J Infect"},{"issue":"11","key":"465_CR71","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1093\/cid\/ciaa1443","volume":"72","author":"JCG de Alencar","year":"2021","unstructured":"de Alencar JCG, Moreira CL, M\u00fcller AD, Chaves CE, Fukuhara MA, da Silva EA, Miyamoto MFS, Pinto VB, Bueno CG, Lazar Neto F, Gomez Gomez LM, Menezes MCS, Marchini JFM, Marino LO, Brand\u00e3o Neto RA, Souza HP, COVID Register Group (2021) Double-blind randomized placebo-controlled With N-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19). Clin Infect Dis 72(11):e736\u2013e741","journal-title":"Clin Infect Dis"},{"key":"465_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-021-00296-2","author":"A Taher","year":"2021","unstructured":"Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya M (2021) A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. https:\/\/doi.org\/10.1007\/s43440-021-00296-2 (Epub ahead of print)","journal-title":"Pharmacol Rep"},{"issue":"1","key":"465_CR73","first-page":"713","volume":"15","author":"P Santus","year":"2020","unstructured":"Santus P, Tursi F, Croce G, Di Simone C, Frassanito F, Gaboardi P, Airoldi A, Pecis M, Negretto G, Radovanovic D (2020) Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidiscip Respir Med 15(1):713","journal-title":"Multidiscip Respir Med"},{"key":"465_CR74","unstructured":"Recipharm. Recipharm\u2019s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment. https:\/\/news.cision.com\/recipharm-ab\/r\/recipharm-s-proprietary-molecule-erdosteine-has-been-positively-tested-as-part-of-covid-19-treatment,c3215696"},{"key":"465_CR75","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/TCRM.S273700","volume":"16","author":"Z Shi","year":"2020","unstructured":"Shi Z, Puyo CA (2020) N-Acetylcysteine to combat COVID-19: an evidence review. Ther Clin Risk Manag 16:1047\u20131055","journal-title":"Ther Clin Risk Manag"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-021-00465-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T14:19:50Z","timestamp":1630678790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-021-00465-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s00408-021-00465-3","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"19 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence what is reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}